Calixa Therapeutics to Make Multiple Presentations on CXA-101 and
CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial
Agents and Chemotherapy
SAN DIEGO, Sept. 11 /PRNewswire/ -- Calixa Therapeutics Inc., a clinical-stage
biopharmaceutical company focused on the development and commercialization of
novel antibiotics for the treatment of antibiotic-resistant infections, will
present pre-clinical and clinical data in 20 posters at the Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held
in San Francisco on September 12 to 15, 2009. The presentations will include
comprehensive in vitro, in vivo, and clinical data on Calixa's
anti-pseudomonal cephalosporin, CXA-101, alone and in combination with the
beta-lactamase inhibitor, tazobactam.
CXA-101 is a potent, intravenously administered, anti-pseudomonal
cephalosporin currently in Phase 2 study for the treatment of complicated
urinary tract infections. Calixa recently initiated a Phase 1 study in
healthy subjects for a second product, CXA-101/tazobactam. Tazobactam is a
well established beta-lactamase inhibitor that could further enhance the
excellent antibacterial activity of CXA-101 and potentially increase its
clinical utility.
"This is an outstanding achievement for Calixa," said James Ge, M.D., Ph.D.,
chief scientific officer and executive vice president, of Calixa. "The 20
presentations give us a very strong presence at this major infectious disease
conference, and reflect significant progress over the past year. We are
particularly enthusiastic about the excellent clinical safety and
pharmacokinetics profile CXA-101 exhibited in the Phase 1 studies conducted to
date. We look forward to moving this promising compound, alone and in
combination with tazobactam, to the next stages of clinical development."
The 20 presentations (F1-1985 to F1- 2004) relating to Calixa's antibiotic
compounds will be presented in the Poster Session, Investigational
Cephalosporins (Tuesday, September 15, 2009, 9:00 to 11:00 AM PDT). The
titles of the presentations are as follows:
F1-1985: Affinity of the New Cephalosporin CXA-101 to Penicillin-Binding
Proteins of Pseudomonas aeruginosa
F1-1986: Activity Profile of CXA-101 and CXA-101/Tazobactam against Target
Gram-Positive and Gram-Negative Pathogens
F1-1987: Activity of the New Cephalosporin CXA-101 against
Carbapenem-Resistant Pseudomonas aeruginosa Isolates from a Spanish
Multicenter Study
F1-1988: CXA-101 has High Activity against Clinical Isolates of Pseudomonas
aeruginosa Including Ceftazidime-Resistant Isolates
F1-1989: Activity of CXA-101 against Pseudomonas aeruginosa beta-lactam
Resistance Mechanisms: ampD, ampDh2, ampDh3, dacB (PBP4), and oprD Mutations
F1-1990: Activity of the New Cephalosporin CXA-101 against Biofilms of
Relevant P. aeruginosa Phenotypes in Cystic Fibrosis Chronic Respiratory
Infection: Mucoid and Hypermutable Strains
F1-1991: Activity of the New Cephalosporin CXA-101 against Biofilms of
Relevant P. aeruginosa Phenotypes in Cystic Fibrosis Chronic Respiratory
Infection: Mucoid and Hypermutable Strains
F1-1992: Activity of the Novel Cephalosporin CXA-101 Tested in Combination
with Tazobactam against Cephalosporin-resistant Enterobacteriaceae, P.
aeruginosa and B. fragilis
F1-1993: Activity of CXA-101 plus Tazobactam against ESBL-Producing
Escherichia coli and Klebsiella pneumoniae
F1-1994: Chequerboard Titrations of Cephalosporin CXA-101 (FR264205) and
Tazobactam vs. Beta-lactamase-producing Enterobacteriaceae
F1-1995: FIC Index Determination of CXA-101/Tazobactam in Combination with
Amikacin, Aztreonam, Meropenem, Levofloxacin, and Tigecycline against E. coli,
K. pneumoniae, and P. aeruginosa Strains.
F1-1996: In Vitro Assessment Using Time-kill Curves of CXA-101
(CXA)/Tazobactam (TAZ) Against Escherichia coli (EC), Klebsiella pneumoniae
(KP), and Pseudomonas aeruginosa (PA) Strains
F1-1997: Quality Control Parameters for CXA-101 Broth Microdilution
Susceptibility Tests
F1-1998: Disk Diffusion Testing of CXA-101 and CXA-101 in Combination with
Tazobactam against Target Pathogens
F1-1999: In Vivo Activity of CXA-101 plus a 2:1, 4:1, or 8:1 Ratio of
Tazobactam against Various Enterobacteriaceae Producing Extended-Spectrum
Beta-Lactamases in the Thighs of Neutropenic Mice
F1-2000: 50% Effective Dose Determination of CXA-101 Alone or in Combination
with Tazobactam for Treating Experimental Peritonitis in Mice Due to
ESBL-Producing Escherichia coli strains: Comparison with Ceftazidime and
Piperacillin/Tazobactam
F1-2001: Pharmacokinetics Study of CXA-101 (CXA) in Combination with
Tazobactam in Dogs after Intravenous Administration
F1-2002: In Vivo Activity of CXA-101, a New Cephalosporin, against Pseudomonas
aeruginosa and other Enterobacteriaceae in the Thighs of Neutropenic Mice
F1-2003: CXA-101 Population PK Analysis and Monte Carlo Simulation for PK/PD
Target Attainment and Dose Regimen Selection
F1-2004: The Pharmacokinetics and Safety of CXA-101, a New Anti-pseudomonal
Cephalosporin, in Healthy Adult Male and Female Subjects Receiving Single- and
Multiple-Dose Intravenous Infusions
About Calixa Therapeutics
Calixa Therapeutics, Inc. is a biopharmaceutical company committed to the
development and commercialization of novel medicines for the treatment of
infectious diseases. The company's initial focus is on developing novel
antibiotics for use in the hospital setting. Calixa Therapeutics, which is
privately held, is headquartered in San Diego and has operations in the San
Francisco Bay Area. For additional information, please visit:
www.calixainc.com.
Contacts:
Robert Flamm, Ph.D., or David Schull
Russo Partners
(212) 845-4226
robert.flamm@russopartnersllc.com
david.schull@russopartnersllc.com
Eckard Weber, M.D.
Calixa Therapeutics Inc.
(858) 480-2420
stone@domainvc.com
SOURCE Calixa Therapeutics Inc.
Robert Flamm, Ph.D., robert.flamm@russopartnersllc.com, or David Schull,
david.schull@russopartnersllc.com, both of Russo Partners, +1-212-845-4226; or
Eckard Weber, M.D. of Calixa Therapeutics Inc., +1-858-480-2420,
stone@domainvc.com
